CClinicalTrials.gg
TerminatedNCT00322582Updated Jan 25, 2012

The Genetic Basis for Familial Cardiomyopathy in Patients With Idiopathic Cardiomyopathy

An observational study in Cardiomyopathy, sponsored by Carmel Medical Center. Terminated at 1 site in Israel. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-01-25.

Sponsored by Carmel Medical Center · Observational

Why this study was terminated
no financial resources were available to complete the study
Study type
Observational
Model
Family-based
Time perspective
Prospective
Enrollment
41
Ages
18 Years to 90 Years
Sex
All
01

Study summary

In many of the patients with cardiomyopathy, the etiology is not clear . In about 30% there is a family history of cardiomyopathy .Our aim is to study the genetics basis for these patients with cardiomyopathy with no clear etiology and who have a first degree family relative with cardiomyopathy as well.

Read the detailed description

A total of 950 blood samples will be collected from patients with idiopathic cardiomyopathy and their relatives and will be analysed for genetics analysis.

02

Conditions studied

  • Cardiomyopathy

Browse trials for

Keywords

  • familial cardiomyopathy
  • genetics analysis
03

In context

Cardiomyopathies

1,176 studies on the registry are indexed under Cardiomyopathies; 287 are open to participants now.

This study's enrollment of 41 is below the median of 153 across 515 observational studies indexed under Cardiomyopathies.

Browse Cardiomyopathies studies →

Lead sponsor

Carmel Medical Center is the lead sponsor of 112 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

History of cardiomyopathy

Inclusion criteria

  • history of cardiomyopathy
  • etiology not known
  • family history of cardiomyopathy
  • ability to understand and sign the informed consent

Exclusion criteria

Exclusion Criteria:

  • refusal to participate
  • pregnancy
  • current participation in another active treatment study
05

Study design

Observational model
Family-based
Time perspective
Prospective
Enrollment
41 participants (actual)
Biospecimen retention
Samples with dna
06

Study locations

1 site
  • Carmel Medical Center
    Haifa, 34362, Israel
07

References and documents

Publications

  • Murphy RT, Starling RC. Genetics and cardiomyopathy: where are we now? Cleve Clin J Med. 2005 Jun;72(6):465-6, 469-70, 472-3 passim. doi: 10.3949/ccjm.72.6.465. PubMed 16018289 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 25, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00322582
Lead sponsor
Carmel Medical Center
Responsible party
Offer Amir (Offer Amir, MD, Carmel Medical Center, Carmel Medical Center) — Principal investigator
First posted
May 8, 2006
Start date
May 2007
Primary completion
Feb 2009
Completion
Feb 2009
Last update
Jan 25, 2012

Study contacts

Offer Amir, MD
study director · Lady Davis Carmel Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion